Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation by Al Malki, Monzr M. et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
2020 
Comparing transplant outcomes in ALL patients after 
haploidentical with PTCy or matched unrelated donor 
transplantation 




Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
REGULAR ARTICLE
Comparing transplant outcomes in ALL patients after haploidentical with
PTCy or matched unrelated donor transplantation
Monzr M. Al Malki,1 Dongyun Yang,2 Myriam Labopin,3 Boris Afanasyev,4 Emanuele Angelucci,5 Asad Bashey,6 Gérard Socié,7
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with ALL who under-
went haploidentical
(n 5 487) or MUD
(n 5 974) transplant.
•HaploHCT with PTCy




(plus or minus ATG)
had comparable
outcomes.
We compared outcomes of 1461 adult patients with acute lymphoblastic leukemia (ALL)
receiving hematopoietic cell transplantation (HCT) from a haploidentical (n 5 487) or
matched unrelated donor (MUD; n 5 974) between January 2005 and June 2018. Graft-
versus-host disease (GVHD) prophylaxis was posttransplant cyclophosphamide (PTCy),
calcineurin inhibitor (CNI), and mycophenolate mofetil (MMF) for haploidentical, and CNI
with MMF or methotrexate with/without antithymoglobulin for MUDs. Haploidentical
recipients were matched (1:2 ratio) with MUD controls for sex, conditioning intensity,
disease stage, Philadelphia-chromosome status, and cytogenetic risk. In the myeloablative
setting, day 128 neutrophil recovery was similar between haploidentical (87%) and MUD
(88%) (P 5 .11). Corresponding rates after reduced-intensity conditioning (RIC) were
84% and 88% (P 5 .47). The 3-month incidence of grade II-IV acute GVHD (aGVHD) and
3-year chronic GVHD (cGVHD) was similar after haploidentical compared with MUD:
myeloablative conditioning, 33% vs 34% (P 5 .46) for aGVHD and 29% vs 31% for cGVHD
(P5 .58); RIC, 31% vs 30% (P5 .06) for aGVHD and 24% vs 29% for cGVHD (P 5 .86). Among
patients receivingmyeloablative regimens, 3-year probabilities of overall survival were 44%
and 51% with haploidentical and MUD (P 5 .56). Corresponding rates after RIC were 43%
and 42% (P 5 .6). In this large multicenter case-matched retrospective analysis, despite the
limitations of a registry-based study (ie, unavailability of key elements such as minimal
residual disease testing), our analysis indicated that outcomes of patients with ALL
undergoing HCT from a haploidentical donor were comparable with 8 of 8 MUD
transplantations.
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Introduction
Allogeneic hematopoietic cell transplantation (HCT; alloHCT) is the
treatment of choice for most adult patients with acute lymphoblastic
leukemia (ALL).1-5 Unfortunately, donor availability remains as one
of the major challenges for transplant success in this patient
population. Although HLA matched sibling donors are the preferred
donors for alloHCT, such donors are available for,30% of patients.
For patients with no matched sibling donor, transplant from a
matched unrelated donor (MUD) has similar transplant outcomes.6
Although the likelihood of finding an 8 of 8 MUD for the white
population is ;70%, this probability falls to ,20% for African
Americans and other ethnic minorities,7 and becomes even more
challenging for mixed-race individuals.8 Unfortunately, an average
of 3 to 4 months is required to identify a MUD and procure
hematopoietic progenitor cells.9
Over the last decade, haploidentical donors have evolved as
an alternative source of donor cells. More than 95% of patients
have at least 1 HLA-haploidentical first-degree donor with an
average number of haploidentical donors available per patient of
2.7.10,11 Historically, the success of T-cell–replete haploidentical
HCT (HaploHCT) was limited by high rates of graft rejection,
graft-versus-host disease (GVHD), and nonrelapse mortality
(NRM).12 In recent years, administration of high-dose posttrans-
plant cyclophosphamide (PTCy), a calcineurin inhibitor (CNI; ie,
tacrolimus, cyclosporine), in combination with mycophenolate
mofetil (MMF) for GVHD prophylaxis after HaploHCT, has shown
lower rates of NRM without significantly compromising engraft-
ment, and comparable rates of GVHD to transplantation from
a matched donor.13,14 Using this strategy, the risk of fatal
infections was also lower, due to the more effective immune
reconstitution, presumably related to retaining more memory
T cells in the graft.15
Several single-center and registry-based studies have compared
T-cell–replete HaploHCT with matched donor transplants in acute
myeloid leukemia and lymphomas, and reported similar outcomes
between these donor sources.16-22 More recently, 2 retrospective
studies have described favorable outcomes of patients with ALL
undergoing HaploHCT with PTCy23,24; a recent retrospective
study by the European Society for Blood and Marrow Trans-
plantation (EBMT) indicated that outcomes of adult patients with
ALL who underwent HaploHCT with or without antithymoglobulin
(ATG; n 5 136) in their first remission are comparable to MUD
(n 5 809) or mismatched unrelated donor (n 5 289) trans-
plants.25 The current study is a matched-pair analysis with detailed
comparison of transplant outcomes in ALL patients who un-
derwent HaploHCT with PTCy-based GVHD prophylaxis and
MUD transplant.
Patients and methods
Data retrieval and inclusion criteria
For patients who underwent MUD HCT (n 5 2871), data were
provided from the Acute Leukemia Working Party (ALWP) of the
EBMT group registry. The EBMT registry is the largest database of
HCT patients in Europe, with .600 transplant centers reporting all
consecutive HCTs and follow-up data once a year. For patients who
underwent HaploHCT, data were obtained from the Haploidentical
Transplant and Cellular Therapy–Research Consortium (TCT-RC)
(n 5 181) and the ALWP of the EBMT (n 5 382). The TCT-RC
is a voluntary working group of 6 transplant centers. Partici-
pating centers to this analysis include City of Hope National
Medical Center (Duarte, CA; n 5 25), MD Anderson Cancer
Center (Houston, TX; n 5 43), Northside Hospital (Atlanta, GA;
n 5 48), Instituto de Cancerologia–Clinica Las Americas
(Medellin, Colombia; n 5 23), Moffitt Cancer Center (Tampa,
FL; n 5 17), and Washington University in St. Louis (St. Louis,
MO; n 5 13).
Adult patients with ALL over 18 years of age who received their
first alloHCT between January 2005 and June 2018 were
included. Recipients of HaploHCT (mismatched at least 2 or
more HLA loci to donors) received predominantly bone marrow
(BM) or unmanipulated peripheral blood (PB) stem cells (PBSCs)
or as the graft source. GVHD prophylaxis for HaploHCT patients
consisted of PTCy (50 mg/kg for 2 days), a CNI, and MMF.
Recipients of MUD HCT (8 of 8 matched at the allele level at
HLA-A, -B, -C, and -DRB1) received unmanipulated graft (PBSC
or BM) and GVHD prophylaxis consisting of a CNI and
minimethotrexate or MMF. ATG was added in 64% of MUD
HCTs. Patients received either myeloablative conditioning (MAC)
or reduced-intensity conditioning (RIC) regimens according to
previously accepted criteria.26 Patients with unknown sex or
conditioning intensity (n 5 36), HaploHCT recipients who
received ATG as GVHD prophylaxis (n 5 30), or patients who
were alive but were followed for ,100 days (n 5 176) were
excluded. The institutional review boards of all participating
centers approved this study.
End points
Overall survival (OS) was defined as time from transplant to death
from any cause. Surviving patients were censored at the last
contact. Relapse-free survival (RFS) was defined as time from
transplant to disease relapse or death of any cause, whichever
came first. RFS was censored at last contact if patients remained
alive and disease-free. GVHD-free RFS events were defined as
the earliest occurrence of grade III-IV acute GVHD, extensive
chronic GVHD, disease relapse, or death from any cause since
transplant. Neutrophil recovery was defined as achieving an
absolute neutrophil count of$0.53 109/L for 3 consecutive days.
Acute and chronic GVHD were graded using standard
criteria.27,28 NRM was defined as time from transplant to death
in continuous complete remission. Relapse was defined as time
from transplant to morphologic, cytogenetic, or molecular
leukemia recurrence. NRM and relapse were competing risk
events to each other.
Statistical analysis
Eligible patients with ALL who underwent HaploHCT at 6 TCT-RC
centers and the ALWP of the EBMT (n 5 512) were matched at
a 1:2 ratio with MUD recipients from the EBMT database (n 5
2680), based on recipient sex, cytogenetic risk, Philadelphia-
chromosome status, disease stage, and conditioning intensity.
MUD recipients were randomly selected if their ratio of MUD to
Haplo was .2:1 in matching strata. HaploHCT patients who had
,2 matched MUD controls were excluded from the analyses (n 5
25). Differences in other baseline patient, donor, and disease
characteristics by donor type were compared using x2 tests or
Wilcoxon tests whenever appropriate. Multivariable Cox regression
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models were constructed to examine the differences in OS or RFS
by donor type when adjusting for the covariates, and classified by
matching strata. Multivariable Fine and Gray models were used to
assess the differences in NRM, relapse, neutrophil engraftment, and
acute or chronic GVHD by donor type when controlling for
covariates, and were classified by matching strata. Backward
stepwise selection at the 0.1 level was used to include covariates
in each final multivariable model. The following covariates were
considered: age (,30 years, 30-39 years, 40-54 years, and $55
years), Karnofsky Performance Status (KPS), disease type,
months from diagnosis to transplant (#6 months, .6-12 months,
and.12 months), female donor to male recipient, donor/recipient
cytomegalovirus (CMV) serostatus, graft source, and transplant
era. Total-body irradiation–based MAC was also considered in the
models among patients who received this conditioning regimen.
The robust sandwich estimates29 were used to take intracenter
correlation (center-effect correlations) into account for the Cox
and Fine and Gray regression models. Differences in clinical
outcomes by donor type were examined in all patients overall, and
by conditioning intensity, separately. The assumption of propor-
tionality was examined using plots of the scaled Schoenfeld
residuals or the cumulative sums of residuals and corresponding
tests.30,31
Statistical analyses were conducted using SAS 9.4 (SAS Institute,
Cary, NC). Two-sided P values were reported. A significance level
of .05 was used for all tests.
Results
Patient, disease, and transplant characteristics
Table 1 shows patient, disease, and transplant characteristics.
Matches were sought for the main variables known to impact outcome
of transplant (ie, cytogenetic risk, Philadelphia-chromosome status,
disease stage prior to HCT, sex, and conditioning intensity).
Compared with MUD, HaploHCT recipients were younger in age
(median age at HCT of 33 years vs 36 years; P 5 .02), received
transplant at a later time after diagnosis (time from diagnosis to
transplant .12 months in 42% vs 36%; P 5 .02), received stem
cells from an older donor (median donor age of 38 years vs
32 years; P , .0001) or a female donor (female donor to male
recipient in 27% vs 13%; P , .0001), and were more likely to
receive BM as the graft source (49% vs 17%; P , .0001).
GVHD prophylaxis in HaploHCT patients consisted of PTCy, a CNI,
and MMF (100%), and MUD patients received a CNI in 98% (or
sirolimus 2%) with methotrexate (68%) and/or MMF (29%). The
majority of HaploHCT recipients received transplants after 2013
(82%), reflecting the recent trend in use of PTCy as a GVHD
prophylaxis for this group of patients.
To investigate the impact of conditioning regimen intensity on
transplant outcomes, we divided patients into 2 subpopulations of
MAC or RIC (supplemental Table 1A). The detailed conditioning
regimen is summarized in supplemental Table 1B. Within the MAC
group, total-body irradiation–based conditioning was used in 49%
in the haploidentical and 75% in the MUD transplant recipients
(P , .0001).
Hematopoietic recovery
Neutrophil recovery rates at day 28 post-HCT were not statistically
different between Haplo (86%) and MUD (88%), (hazard ratio
[HR] 5 1.08; 95% confidence interval [CI], 0.95-1.24; P 5 .24)
(supplemental Table 2). In subgroup analysis, using a multivariable
regression model, when BM was used as the graft source,
a significantly faster neutrophil engraftment was observed in
patients undergoing HaploHCT (HR 5 1.27; 95% CI, 1.01-1.59;
P5 .038). Engraftment was not different in patients who underwent
a transplant in first complete remission (CR1), or received MAC or
RIC, and PBSCs as the graft source in Haplo vs MUD HCT
(supplemental Table 3).
Survival outcomes
With a median follow-up of 3.0 years (range, 0.3-12.6 years), OS
and RFS at 3 years posttransplant were not different between
recipients of Haplo and MUD HCT (OS [HR5 1.09; 95% CI, 0.89-
1.33; P 5 .43]; RFS [HR 5 1.05; 95% CI, 0.87-1.27; P 5 .60])
(Table 2). The 3-year probabilities of GVHD-free RFS for this cohort
was 31% (95% CI, 26% to 37%) in HaploHCT as compared with
32% (95% CI, 29% to 36%) in MUD HCT recipients (HR 5 1.06;
95% CI, 0.91-1.22; P 5 .47).
In multivariable analysis, when recipient age above 30 years was
assigned as the reference, HRs of 1.29 (95% CI, 1.06-1.57),
1.34 (95% CI, 1.11-1.61), and 1.92 (95% CI, 1.50-2.45) were
achieved for recipient ages at 30 to 39 years, 40 to 54 years, and
$55 years, respectively (P , .001); KPS of #80% (HR 5 1.51;
95% CI, 1.28-1.79; P, .001) was also found to be a predictor of
lower 3-year OS and RFS (Table 2). Other variables tested
using the regression model, including ALL subtype, time from
diagnosis to transplant, donor age and sex, CMV status, and
stem cell source, were not predictors of survival outcomes. In
subgroup analysis, no differences were detected when survival
outcomes were compared between recipients of Haplo and
MUD HCT based on the intensity of conditioning regimen
(Figure 1), remission status (CR1), graft source, and different
disease groups of Ph1 ALL, Ph2 ALL, and T-cell ALL (supplemental
Table 3).
Approximately two-thirds of the MUD HCT recipients (64%)
received ATG (Table 1). When we investigated the effect of ATG
administration on survival outcomes, no statistical significance
was detected. Compared with haploidentical transplants, mor-
tality risks for non-ATG and ATG-containing regimens in MUD
HCT recipients were similar (HR 5 0.86; 95% CI, 0.68-1.09;
P 5. 22).
Relapse and NRM
In multivariable analysis, after adjusting for potential confounders,
age above 40 years predicted for higher rate of NRM at 3 years
post-HCT (HR 5 1.33 [95% CI, 1.01-1.76] and 1.73 [95% CI,
1.26-2.36] for 40-54 years and$55 years, respectively; P, .001).
Moreover, KPS #80 also predicted for higher NRM (with HR 5
1.50 [95% CI, 1.18-1.89]; P , .001). ALL subtype, months from
diagnosis to HCT, female donor to male recipient, donor age, CMV
status, and stem cell source did not affect either NRM or relapse
(Table 3).
In the subgroup analysis, no differences were noted in either
disease relapse or NRM when recipients of Haplo and MUD HCT
were compared based on intensity of the conditioning regimen,
CR1 status, Philadelphia-chromosome status, and graft source
(supplemental Table 4).
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Acute and chronic GVHD
Acute and chronic GVHD rates and severity were not different in
patients undergoing Haplo or MUD transplantation (Tables 4 and
5). In multivariable analysis, patients who received transplants
using a BM graft as their graft source experienced lower rates of
grade II-IV acute GVHD compared with those who received
transplants using PBSCs (HR 5 0.69; 95% CI, 0.55-0.87; P ,
.001) (Table 4). Rates of chronic GVHD were lower in patients
with KPS # 80% (HR 5 0.75; 95% CI, 0.58-0.98; P 5 .033)
(Table 5).
Incidence and severity of acute GVHD and chronic GVHD in
subgroup analysis are summarized in supplemental Table 5A-B. The






(n 5 974) P
Age at transplant, y .018
Median (range) 35 (18-76) 33 (18-73) 36 (18-76)
Interquartile range 25, 49 24, 46 25, 50
,30 579 (40) 208 (43) 371 (38) .12
30-39 281 (19) 98 (20) 183 (19)
40-54 350 (24) 111 (23) 239 (25)
$55 251 (17) 70 (14) 181 (19)
Recipient sex 1.0
Male 909 (62) 303 (62) 606 (62)
Female 552 (38) 184 (38) 368 (38)
KPS .0001
90-100 978 (67) 321 (66) 657 (67)
#80 388 (27) 151 (31) 237 (24)
NA 95 (7) 15 (3) 80 (8)
Cytogenetic risk 1.0
Poor risk 489 (33) 163 (33) 326 (33)




Ph1 351 (24) 117 (24) 234 (24)
Ph2 1110 (76) 370 (76) 740 (76)
Disease stage prior to HCT 1.0
CR1 768 (53) 256 (53) 512 (53)
CR21 468 (32) 156 (32) 312 (32)
Active disease 225 (15) 75 (15) 150 (15)
ALL type .66
B-ALL 1044 (71) 345 (71) 699 (72)
T-ALL 322 (22) 113 (23) 209 (21)
Other 95 (7) 29 (6) 66 (7)
From diagnosis to transplant,
mo
.024
#6 398 (27) 114 (23) 284 (29)
.6-12 510 (35) 168 (34) 342 (35)
.12 553 (38) 205 (42) 348 (36)
HCT Comorbidity Index ,.0001
0 147 (10) 98 (20) 49 (5)
1-2 92 (6) 71 (15) 21 (2)
.2 94 (6) 82 (17) 12 (1)
NA 1128 (77) 236 (48) 892 (92)
Donor age, y† ,.0001
Median (range) 34 (13-76) 38 (13-76) 32 (18-62)
Interquartile range 26, 45 26, 49 26, 40
,30 342 (23) 146 (30) 196 (20) ,.0001
30-50 443 (30) 200 (41) 243 (25)
$50 127 (9) 104 (21) 23 (2)







(n 5 974) P
Donor sex ,.0001
Male 966 (66) 276 (57) 690 (71)
Female 468 (32) 211 (43) 257 (26)
NA 27 (2) 27 (3)
Female donor to male
recipient
,.0001
Yes 262 (18) 131 (27) 131 (13)
No 1172 (80) 356 (73) 816 (84)




D2/R2 318 (22) 43 (9) 275 (28)
D2/R1 366 (25) 84 (17) 282 (29)
D1/R2 130 (9) 41 (8) 89 (9)
D1/R1 581 (40) 303 (62) 278 (29)
Unknown 66 (5) 16 (3) 50 (5)
Conditioning intensity 1.0
Myeloablative 1074 (74) 358 (74) 716 (74)
Reduced 387 (26) 129 (26) 258 (26)
Stem cell source ,.0001
BM 405 (28) 237 (49) 168 (17)
PBMC 1056 (72) 250 (51) 806 (83)
GVHD prophylaxis
Sirolimus-based 23 (2) 23 (2)
MTX-based 664 (45) 664 (68)
CellCept-based 287 (20) 287 (29)
PTCy/CellCept/CNI 487 (33) 487 (100)
ATG added 626 (43) 0 (0) 626 (64)
Transplant period ,.0001
2005-2012 695 (48) 86 (18) 609 (63)
2013-2018 766 (52) 401 (82) 365 (37)
B-ALL, B-cell ALL; CR1, first complete remission; CR2, second complete remission; D,
donor; MTX, methotrexate; NA, not applicable; PBMC, peripheral blood mononuclear cell;
R, recipient; T-ALL, T-cell ALL.
*Values expressed as n (%), unless otherwise specified in a row heading.
†For the “Donor age” section only: Total, N 5 912; Haplo, n 5 450; MUD, n 5 462.
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only subsets with a statistically meaningful difference in the
incidence of grade III-IV acute GVHD were in recipients of MUD
vs Haplo HCT, MUD as the reference group, in the subset of
patients who received RIC (with HR 5 2.19; 95% CI, 1.08-4.44;
P 5 .030) or PBSC as the graft source (with HR 5 1.49; 95% CI,
1.02-2.18; P 5 .041).
Table 2. Survival outcomes
n
OS RFS
3-y (95% CI) Adjusted HR (95% CI)* P* 3-y (95% CI) Adjusted HR (95% CI)* P*
Donor type
MUD 974 0.48 (0.45, 0.52) Reference .43 0.42 (0.39, 0.45) Reference .60
Haplo 487 0.43 (0.38, 0.49) 1.09 (0.89, 1.33) 0.39 (0.34, 0.44) 1.05 (0.87, 1.27)
Recipient age, y
,30 579 0.53 (0.49, 0.57) Reference ,.001 0.48 (0.43, 0.52) Reference ,.001
30-39 281 0.47 (0.40, 0.53) 1.29 (1.06, 1.57) 0.40 (0.33, 0.46) 1.32 (1.09, 1.60)
40-54 350 0.46 (0.40, 0.51) 1.34 (1.11, 1.61) 0.42 (0.36, 0.47) 1.29 (1.08, 1.54)
$55 251 0.34 (0.28, 0.41) 1.92 (1.50, 2.45) 0.27 (0.21, 0.33) 1.83 (1.43, 2.34)
KPS†
90-100 978 0.51 (0.47, 0.54) Reference ,.001 0.44 (0.40, 0.47) Reference ,.001
#80 388 0.36 (0.31, 0.41) 1.51 (1.28, 1.79) 0.33 (0.28, 0.38) 1.35 (1.15, 1.58)
ALL subtype
B-ALL 1044 0.48 (0.44, 0.51) Reference .71 0.42 (0.39, 0.45) Reference .68
T-ALL 322 0.46 (0.40, 0.52) 1.00 (0.82, 1.22) 0.38 (0.33, 0.44) 1.08 (0.90, 1.30)
Other 95 0.41 (0.30, 0.52) 1.12 (0.84, 1.50) 0.38 (0.26, 0.49) 1.00 (0.74, 1.35)
Months from diagnosis to HCT
#6 398 0.55 (0.50, 0.61) Reference .33 0.47 (0.41, 0.52) Reference .68
.6-12 510 0.50 (0.45, 0.55) 1.15 (0.95, 1.38) 0.47 (0.43, 0.52) 1.05 (0.88, 1.24)
.12 553 0.38 (0.33, 0.42) 1.15 (0.92, 1.45) 0.31 (0.27, 0.35) 1.10 (0.89, 1.37)
HCT Comorbidity Index†
0 147 0.57 (0.45, 0.67) Reference .14 0.43 (0.31, 0.55) Reference .30
1-2 92 0.28 (0.16, 0.43) 1.52 (0.95, 2.42) 0.29 (0.18, 0.42) 1.34 (0.89, 2.02)
.2 94 0.42 (0.27, 0.57) 0.95 (0.61, 1.49) 0.39 (0.25, 0.53) 0.95 (0.66, 1.36)
Donor age, y†
,30 342 0.44 (0.38, 0.50) Reference .62 0.39 (0.33, 0.45) Reference .45
30-49 443 0.47 (0.42, 0.52) 0.97 (0.80, 1.17) 0.42 (0.37, 0.47) 0.96 (0.81, 1.15)
$50 127 0.45 (0.35, 0.55) 1.11 (0.80, 1.55) 0.41 (0.31, 0.50) 1.12 (0.84, 1.50)
Female donor to male recipient†
No 1172 0.47 (0.44, 0.50) Reference .86 0.41 (0.38, 0.44) Reference .54
Yes 262 0.47 (0.40, 0.54) 0.98 (0.81, 1.19) 0.39 (0.32, 0.45) 1.06 (0.89, 1.25)
CMV serostatus†
D1/R1 581 0.46 (0.41, 0.50) Reference .41 0.39 (0.35, 0.44) Reference .63
D1/R2 130 0.49 (0.39, 0.57) 0.96 (0.75, 1.23) 0.46 (0.37, 0.54) 0.94 (0.74, 1.21)
D2/R1 366 0.47 (0.41, 0.53) 0.90 (0.73, 1.11) 0.43 (0.37, 0.48) 0.88 (0.73, 1.07)
D2/R2 318 0.50 (0.44, 0.56) 0.83 (0.67, 1.04) 0.41 (0.35, 0.47) 0.97 (0.80, 1.18)
Stem cell source
PB 1056 0.48 (0.45, 0.51) Reference .082 0.42 (0.38, 0.45) Reference .074
BM 405 0.44 (0.38, 0.49) 1.18 (0.98, 1.42) 0.39 (0.34, 0.44) 1.18 (0.98, 1.42)
Transplant period
2005-2012 695 0.47 (0.43, 0.50) Reference .80 0.42 (0.38, 0.46) Reference .52
2013-2018 766 0.46 (0.42, 0.51) 0.98 (0.83, 1.16) 0.39 (0.35, 0.44) 1.05 (0.90, 1.22)
*Based on the multivariable Cox regression model adjusted for recipient age, KPS, and stem cell source, and stratified by matching variables: sex, cytogenetic risk, Ph status, disease
stage, and conditioning intensity. The robust sandwich covariance matrix estimate was used to adjust for within-center correlation.
†Patients who had missing values were included in the model when the variable was covariates, but were excluded when the variable was predictor of interest.

















L user on 11 Septem
ber 2020
Causes of death
There were no significant differences in cause-specific death
between HaploHCT and MUD HCT for disease relapse/pro-
gression (P 5 .78), infections (P 5 .82), or organ failure (P 5
.20). However, patients of Haplo HCT were less likely to die of
GVHD compared with MUD recipients (HR 5 0.45; 95% CI, 0.26-
0.76; P 5 .003).
Discussion
In this study, we retrospectively analyzed and compared sur-
vival and other transplant outcomes of patients with ALL who
underwent haploidentical transplantation with PTCy-based
GVHD prophylaxis (data from TCT-RC, ALWP, and EBMT), with
patients who received a MUD transplant (data from ALWP and
EBMT) during the same period of time. We matched (1:2 ratio)
a cohort of patients with ALL who underwent HaploHCT (n 5
506) or MUD transplants (n 5 1012) for factors known to predict
transplant outcome.1,4,5,23,24 Posttransplant survival was ad-
justed for other factors, independent of donor type including age,
KPS, time from diagnosis to transplant, and stem cell type. Our
results indicated that in patients with ALL, OS after HaploHCT
with PTCy was comparable to MUD HCT with conventional
GVHD prophylaxis (with or without ATG), regardless of the
intensity of the conditioning regimen.
In agreement with recently published data by Shem-Tov et al from
the ALWP of EBMT,25 our analysis demonstrated that outcomes of
alloHCT from haploidentical donors were comparable to MUD
transplants for ALL patients. In the current study, we further
demonstrated that outcomes in HaploHCT were not different from
MUD HCT regardless of conditioning intensity, Philadelphia-
chromosome status, and PBSCs as graft source. However, similar
to what was previously reported by Bashey et el,32 when PBMC
was used as the graft source, a statistically significant increase in
the incidence of grade II-IV acute GVHD was detected in recipients
of HaploHCT. Although our results need to be further investigated,
our analysis suggests that PTCy has a more substantial contribution
to lowering the incidence of acute GVHD when BM is used as the
graft source, possibly due to the lower number of alloreactive T cells
in the BM compared with the mobilized PB. In our analysis, rate of
acute GVHD was lower in female donor to male recipient in
HaploHCT compared with MUD, suggesting that PTCy-based
therapy could impact high rates of acute GVHD in female-to-male
HCT; however, this was not the case in chronic GVHD.
Overall, the incidence of acute and chronic GVHD was similar after
Haplo or MUD HCT, but the mortality rate related to GVHD was
higher in patients who received transplantation from a MUD with
standard GVHD prophylaxis. The similarity in GVHD rate could be at
least partly explained by the intensive GVHD prophylaxis including
in vivo T-cell depletion with ATG in a majority of patients in the MUD
cohort. It is important to emphasize that in the study by Shem-Tov
et al, the incidence of acute and chronic GVHD was not different in
Haplo vs unrelated donors. However, 15% of patients in the
HaploHCT cohort were given PTCy and ATG, whereas in our study,
we limited our analysis to a more homogenous group of patients
who received PTCy alone as the GVHD prophylaxis. In this study,
patients undergoing HaploHCT were more likely to develop grade
III-IV GVHD compared with MUD recipients in subgroup analyses of
RIC and PBSCs.
Although the present study is 1 of the first comprehensive
comparisons of outcomes of Haplo and MUD HCT in patients with
ALL, it has several limitations. Being at least in part an EBMT
registry-based study, some of the key elements including minimal
residual disease testing, platelet engraftment, and response to prior
treatment and HCT Comorbidity Index (77% missing) were partially
missing. Although every attempt was made to match or adjust for
factors important to predict transplant outcomes, our analysis
carried the inherited biases of a retrospective analysis. The wide
range of conditioning intensity that existed within the 2 main groups
(MAC and RIC) represented another layer of heterogeneity, adding
another bias in this comparative study.
There is an increasing interest, and there are promising results, in
the use of PTCy as GVHD prophylaxis after alloHCT.33-35 However,
data allowing the comparison between transplant outcomes after
Haplo and MUD HCT, using PTCy as GVHD prophylaxis, were not
available for our analysis, and a comparison between Haplo and
MUD HCT with the same GVHD prophylaxis is needed and remains









































Figure 1. Comparison of survival outcomes between patients undergoing Haplo and MUD HCT. (A) OS post-MAC. (B) OS post-RIC.
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Table 3. Relapse and NRM
n
Relapse NRM
3-y (95% CI) HR (95% CI)* P* 3-y (95% CI) HR (95% CI)* P*
Donor type
MUD 974 0.34 (0.31, 0.37) Reference .68 0.24 (0.21, 0.27) Reference .19
Haplo 487 0.37 (0.32, 0.41) 0.95 (0.75, 1.21) 0.24 (0.20, 0.29) 1.19 (0.92, 1.55)
Recipient age, y
,30 579 0.31 (0.27, 0.36) Reference .038 0.21 (0.18, 0.25) Reference .006
30-39 281 0.40 (0.34, 0.46) 1.34 (1.05, 1.72) 0.20 (0.16, 0.25) 1.10 (0.80, 1.49)
40-54 350 0.33 (0.27, 0.38) 1.15 (0.90, 1.46) 0.26 (0.21, 0.31) 1.33 (1.01, 1.76)
$55 251 0.40 (0.34, 0.47) 1.39 (1.07, 1.82) 0.33 (0.27, 0.39) 1.73 (1.26, 2.36)
KPS†
90-100 978 0.35 (0.32, 0.38) Reference .76 0.21 (0.18, 0.24) Reference ,.001
#80 388 0.36 (0.31, 0.41) 0.97 (0.79, 1.19) 0.31 (0.26, 0.36) 1.50 (1.18, 1.89)
ALL subtype
B-ALL 1044 0.33 (0.30, 0.36) Reference .56 0.25 (0.22, 0.27) Reference .70
T-ALL 322 0.39 (0.33, 0.44) 1.10 (0.89, 1.37) 0.23 (0.18, 0.28) 1.00 (0.75, 1.33)
Other 95 0.40 (0.28, 0.51) 1.15 (0.79, 1.65) 0.22 (0.14, 0.32) 0.83 (0.53, 1.30)
Months from diagnosis to HCT
#6 398 0.32 (0.27, 0.37) Reference .25 0.21 (0.17, 0.26) Reference .11
.6-12 510 0.28 (0.24, 0.32) 0.80 (0.62, 1.04) 0.24 (0.21, 0.28) 1.31 (0.99, 1.73)
.12 553 0.43 (0.39, 0.48) 0.86 (0.65, 1.14) 0.26 (0.22, 0.29) 1.41 (0.98, 2.03)
HCT Comorbidity Index†
0 147 0.34 (0.24, 0.44) Reference .89 0.23 (0.14, 0.32) Reference .39
1-2 92 0.43 (0.30, 0.55) 1.09 (0.66, 1.78) 0.28 (0.18, 0.38) 1.36 (0.79, 2.34)
.2 94 0.36 (0.26, 0.47) 0.96 (0.57, 1.61) 0.24 (0.12, 0.39) 0.95 (0.52, 1.74)
Donor age, y†
,30 342 0.37 (0.31, 0.43) Reference .99 0.24 (0.19, 0.29) Reference .50
30-49 443 0.37 (0.32, 0.42) 0.99 (0.77, 1.27) 0.21 (0.18, 0.26) 0.94 (0.69, 1.27)
$50 127 0.33 (0.25, 0.42) 0.99 (0.69, 1.41) 0.26 (0.18, 0.34) 1.19 (0.78, 1.81)
Female-to-male HCT†
No 1172 0.34 (0.31, 0.37) Reference .087 0.24 (0.22, 0.27) Reference .70
Yes 262 0.39 (0.33, 0.46) 1.22 (0.97, 1.53) 0.22 (0.17, 0.27) 0.94 (0.70, 1.27)
CMV serostatus†
D1/R1 581 0.37 (0.33, 0.41) Reference .062 0.24 (0.20, 0.28) Reference .14
D1/R2 130 0.30 (0.22, 0.38) 0.89 (0.62, 1.28) 0.24 (0.17, 0.32) 1.11 (0.78, 1.58)
D2/R1 366 0.32 (0.27, 0.37) 0.85 (0.67, 1.07) 0.25 (0.20, 0.30) 1.04 (0.79, 1.36)
D2/R2 318 0.40 (0.34, 0.45) 1.22 (0.96, 1.56) 0.19 (0.15, 0.24) 0.74 (0.54, 1.02)
Stem cell source
PB 1056 0.35 (0.32, 0.38) Reference .41 0.24 (0.21, 0.26) Reference .40
BM 405 0.36 (0.31, 0.41) 1.09 (0.88, 1.35) 0.25 (0.21, 0.29) 1.12 (0.87, 1.44)
Transplant period
2005-2012 695 0.32 (0.28, 0.35) Reference .099 0.26 (0.23, 0.29) Reference .027
2013-2018 766 0.38 (0.34, 0.42) 1.17 (0.97, 1.41) 0.23 (0.19, 0.26) 0.78 (0.63, 0.97)
*Based on the multivariable proportional subdistribution hazards model for competing risks adjusted for age, female donor to male recipient, CMV serostatus, and transplant period for
relapse, adjusted for age, KPS, and transplant period for NRM, and stratified by matching variables: sex, cytogenetic risk, Ph status, disease stage, and conditioning intensity. The robust
sandwich covariance matrix estimate was used to adjust for within-center correlation.
†Patients who had missing values were included in the model when the variable was covariates, but were excluded when the variable was predictor of interest.
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a smaller number of transplant centers (100 centers), whereas
MUD HCT was performed in more centers (201 centers),
representing a normal clinical practice across different small-,
mid-, and large-sized transplant centers. The center effect on
HCT outcomes among Haplo and MUD recipients is warranted
and will be important.
Table 4. Acute GVHD
n
Grade II-IV acute GVHD Grade III-IV acute GVHD
100-d (95% CI) HR (95% CI)* P* 100-d (95% CI) HR (95% CI)* P*
Donor type
MUD 974 0.33 (0.30, 0.36) Reference .21 0.12 (0.10, 0.14) Reference .11
Haplo 487 0.32 (0.28, 0.37) 1.13 (0.93, 1.38) 0.14 (0.11, 0.17) 1.30 (0.94, 1.80)
Recipient age, y
,30 579 0.36 (0.32, 0.40) Reference .068 0.15 (0.12, 0.18) Reference .07
30-39 281 0.32 (0.26, 0.37) 0.85 (0.66, 1.10) 0.13 (0.09, 0.17) 0.82 (0.56, 1.22)
40-54 350 0.33 (0.28, 0.38) 0.86 (0.68, 1.09) 0.10 (0.07, 0.14) 0.63 (0.42, 0.94)
$55 251 0.27 (0.22, 0.33) 0.69 (0.52, 0.92) 0.10 (0.07, 0.14) 0.61 (0.38, 0.98)
KPS†
90-100 978 0.33 (0.30, 0.36) Reference 1.00 0.14 (0.11, 0.16) Reference .16
#80 388 0.33 (0.28, 0.38) 1.00 (0.81, 1.23) 0.10 (0.07, 0.14) 0.77 (0.53, 1.11)
ALL subtype
B-ALL 1044 0.33 (0.30, 0.36) Reference .94 0.13 (0.11, 0.15) Reference .65
T-ALL 322 0.31 (0.26, 0.36) 1.04 (0.82, 1.33) 0.10 (0.07, 0.14) 0.89 (0.58, 1.36)
Other 95 0.35 (0.25, 0.45) 1.03 (0.73, 1.43) 0.15 (0.09, 0.24) 1.19 (0.70, 2.02)
Months from diagnosis to HCT
#6 398 0.33 (0.28, 0.38) Reference .44 0.11 (0.08, 0.14) Reference .33
.6-12 510 0.35 (0.30, 0.39) 1.16 (0.91, 1.48) 0.13 (0.10, 0.16) 1.34 (0.90, 2.01)
.12 553 0.31 (0.27, 0.35) 1.05 (0.78, 1.43) 0.13 (0.11, 0.16) 1.31 (0.79, 2.16)
HCT Comorbidity Index†
0 147 0.35 (0.28, 0.43) Reference .90 0.14 (0.09, 0.20) Reference .68
1-2 92 0.37 (0.27, 0.47) 1.10 (0.73, 1.66) 0.16 (0.09, 0.24) 1.21 (0.62, 2.36)
.2 94 0.41 (0.31, 0.51) 1.07 (0.64, 1.78) 0.12 (0.06, 0.19) 0.88 (0.39, 2.00)
Donor age, y†
,30 342 0.38 (0.33, 0.43) Reference .42 0.14 (0.11, 0.18) Reference .90
30-49 443 0.34 (0.29, 0.38) 0.86 (0.68, 1.09) 0.13 (0.10, 0.16) 0.92 (0.61, 1.37)
$50 127 0.35 (0.26, 0.43) 0.97 (0.71, 1.34) 0.14 (0.08, 0.20) 0.92 (0.55, 1.54)
Female-to-male HCT†
No 1172 0.33 (0.30, 0.36) Reference .80 0.13 (0.11, 0.15) Reference .37
Yes 262 0.34 (0.28, 0.40) 1.03 (0.80, 1.32) 0.11 (0.08, 0.16) 0.82 (0.54, 1.26)
CMV serostatus†
D1/R2 581 0.31 (0.28, 0.35) Reference .88 0.11 (0.09, 0.14) Reference .43
D2/R2 130 0.34 (0.26, 0.43) 1.08 (0.78, 1.50) 0.14 (0.09, 0.21) 1.23 (0.71, 2.13)
D2/R2 366 0.33 (0.28, 0.38) 0.98 (0.78, 1.22) 0.11 (0.08, 0.14) 0.89 (0.60, 1.34)
D2/R2 318 0.36 (0.31, 0.41) 1.07 (0.84, 1.35) 0.15 (0.11, 0.19) 1.23 (0.84, 1.79)
Stem cell source
PB 1056 0.35 (0.32, 0.38) Reference .001 0.13 (0.11, 0.15) Reference .14
BM 405 0.26 (0.22, 0.31) 0.69 (0.55, 0.87) 0.10 (0.08, 0.14) 0.76 (0.53, 1.09)
Transplant period
2005-2012 695 0.32 (0.29, 0.36) Reference .42 0.12 (0.09, 0.14) Reference .31
2013-2018 766 0.33 (0.30, 0.37) 1.08 (0.90, 1.30) 0.13 (0.11, 0.16) 1.17 (0.87, 1.57)
*Based on the multivariable proportional subdistribution hazards model for competing risks adjusted for age and stem cell source, and stratified by matching variables: sex, cytogenetic risk,
Ph status, disease stage, and conditioning intensity. The robust sandwich covariance matrix estimate was used to adjust for within-center correlation.
†Patients who had missing values were included in the model when the variable was covariates, but were excluded when the variable was predictor of interest.
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In conclusion, in this large multicenter retrospective analysis,
outcomes of patients with ALL undergoing transplantation from
a haploidentical donor with PTCy were comparable with those
undergoing 8 of 8 MUD HCT using conventional GVHD pro-
phylaxis, with or without ATG. Prospective studies with intention to
treat are required to confirm these results.
Table 5. Chronic GVHD
n
Any chronic GVHD Extensive chronic GVHD
3-y (95% CI) HR (95% CI)* P* 3-y (95% CI) HR (95% CI)* P*
Donor type
MUD 974 0.30 (0.27, 0.34) Reference .50 0.13 (0.10, 0.15) Reference 1.00
Haplo 487 0.28 (0.24, 0.32) 1.09 (0.85, 1.39) 0.09 (0.07, 0.12) 1.00 (0.69, 1.45)
Recipient age, y
,30 579 0.31 (0.27, 0.35) Reference .76 0.11 (0.08, 0.14) Reference .57
30-39 281 0.28 (0.23, 0.34) 0.87 (0.67, 1.14) 0.13 (0.09, 0.17) 1.24 (0.81, 1.89)
40-54 350 0.30 (0.25, 0.36) 0.94 (0.73, 1.21) 0.12 (0.09, 0.16) 1.02 (0.69, 1.52)
$55 251 0.28 (0.22, 0.34) 0.89 (0.65, 1.22) 0.11 (0.07, 0.15) 0.86 (0.53, 1.41)
KPS†
90-100 978 0.31 (0.28, 0.34) Reference .033 0.11 (0.09, 0.14) Reference .48
#80 388 0.24 (0.20, 0.29) 0.75 (0.58, 0.98) 0.11 (0.08, 0.14) 0.87 (0.59, 1.28)
ALL subtype
B-ALL 1044 0.31 (0.28, 0.34) Reference .72 0.12 (0.10, 0.14) Reference .66
T-ALL 322 0.28 (0.23, 0.33) 0.97 (0.76, 1.24) 0.10 (0.07, 0.14) 0.91 (0.60, 1.40)
Other 95 0.25 (0.15, 0.36) 0.83 (0.52, 1.31) 0.09 (0.04, 0.17) 0.71 (0.32, 1.57)
Months from diagnosis to HCT
#6 398 0.34 (0.29, 0.39) Reference .45 0.13 (0.10, 0.17) Reference .098
.6-12 510 0.30 (0.25, 0.34) 0.89 (0.69, 1.14) 0.10 (0.07, 0.13) 0.80 (0.52, 1.23)
.12 553 0.26 (0.22, 0.30) 1.04 (0.75, 1.44) 0.12 (0.09, 0.15) 1.35 (0.80, 2.26)
HCT Comorbidity Index†
0 147 0.27 (0.19, 0.36) Reference .81 0.09 (0.05, 0.14) Reference .39
1-2 92 0.27 (0.18, 0.37) 1.20 (0.68,2.10) 0.14 (0.07, 0.22) 1.72 (0.74, 4.00)
.2 94 0.25 (0.16, 0.36) 1.13 (0.60, 2.13) 0.13 (0.06, 0.22) 1.60 (0.65, 3.97)
Donor age, y†
,30 342 0.30 (0.25, 0.36) Reference .49 0.12 (0.09, 0.16) Reference .65
30-49 443 0.33 (0.29, 0.38) 1.06 (0.81, 1.40) 0.12 (0.09, 0.16) 0.94 (0.60, 1.46)
$50 127 0.25 (0.18, 0.34) 0.84 (0.57, 1.24) 0.08 (0.04, 0.14) 0.72 (0.35, 1.45)
Female-to-male HCT†
No 1172 0.30 (0.27, 0.33) Reference .95 0.12 (0.10, 0.14) Reference .83
Yes 262 0.29 (0.23, 0.35) 1.01 (0.76, 1.34) 0.10 (0.07, 0.14) 1.06 (0.65, 1.71)
CMV serostatus†
D1/R1 581 0.29 (0.25, 0.33) Reference .94 0.11 (0.08, 0.14) Reference .88
D1/R2 130 0.30 (0.22, 0.38) 0.96 (0.66, 1.39) 0.13 (0.08, 0.20) 1.07 (0.62, 1.84)
D2/R1 366 0.28 (0.23, 0.33) 0.98 (0.75, 1.27) 0.11 (0.08, 0.15) 1.00 (0.65, 1.53)
D2/R2 318 0.33 (0.28, 0.39) 1.06 (0.80, 1.40) 0.11 (0.08, 0.15) 0.86 (0.55, 1.34)
Stem cell source
PB 1056 0.30 (0.27, 0.33) Reference .72 0.12 (0.10, 0.14) Reference .25
BM 405 0.28 (0.24, 0.33) 0.96 (0.76, 1.20) 0.10 (0.07, 0.13) 0.80 (0.55, 1.17)
Transplant period
2005-2012 695 0.32 (0.28, 0.36) Reference .009 0.14 (0.12, 0.17) Reference ,.001
2013-2018 766 0.27 (0.24, 0.31) 0.77 (0.63, 0.94) 0.09 (0.07, 0.11) 0.55 (0.40, 0.77)
*Based on the multivariable proportional subdistribution hazards model for competing risks adjusted for KPS, months from diagnosis to HCT, and transplant period, and stratified by
matching variables: sex, cytogenetic risk, Ph status, disease stage, and conditioning intensity. The robust sandwich covariance matrix estimate was used to adjust for within-center correlation.
†Patients who had missing values were included in the model when the variable was covariates, but were excluded when the variable was predictor of interest.
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